

Stuart Elborn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3507842/publications.pdf>

Version: 2024-02-01

11
papers

184
citations

1307594

7
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

280
citing authors

#	ARTICLE	IF	CITATIONS
1	Bronchiectasis and inhaled tobramycin: A literature review. <i>Respiratory Medicine</i> , 2022, 192, 106728.	2.9	11
2	Antimicrobial resistance: Concerns of healthcare providers and people with CF. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 407-412.	0.7	13
3	Therapeutic Inhibition of Cathepsin S Reduces Inflammation and Mucus Plugging in Adult $\hat{2}$ ENaC-Tg Mice. <i>Mediators of Inflammation</i> , 2021, 2021, 1-10.	3.0	3
4	Management of chronic <i>Pseudomonas aeruginosa</i> infection with inhaled levofloxacin in people with cystic fibrosis. <i>Future Microbiology</i> , 2021, 16, 1087-1104.	2.0	7
5	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 370-375.	0.7	24
6	Infection with <i>Prevotella nigrescens</i> induces TLR2 signalling and low levels of p65 mediated inflammation in Cystic Fibrosis bronchial epithelial cells. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 211-218.	0.7	8
7	Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 688-695.	0.7	14
8	Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 50, 72-79.	2.6	45
9	Airway persistence by the emerging multi-azole-resistant <i>Rasamsonia argillacea</i> complex in cystic fibrosis. <i>Mycoses</i> , 2018, 61, 665-673.	4.0	13
10	CFTR Modulators: Deciding What Is Best for Individuals in an Era of Precision Medicine. <i>Annals of the American Thoracic Society</i> , 2018, 15, 298-300.	3.2	6
11	Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic <i>Pseudomonas aeruginosa</i> airway infection. <i>Journal of Cystic Fibrosis</i> , 2016, 15, 634-640.	0.7	40